文献速递心律失常心力衰竭与心肌病

传导系统起搏与右室间隔起搏在房室传导阻滞中的临床结局:CSPACE随机对照试验

Clinical Outcomes of Conduction System Pacing vs Right Ventricular Septal Pacing in Atrioventricular Block: The CSPACE Randomized Controlled Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

CSPACE随机对照试验纳入202例有起搏指征的房室传导阻滞患者,1:1随机分配至右室间隔起搏或传导系统起搏。平均随访25.2个月,传导系统起搏组主要复合终点事件率显著低于右室间隔起搏组(7.17 vs 20.69事件/100人年,HR 0.35,95%CI 0.19-0.64,P<0.001),主要由起搏诱导性心肌病和升级至双室CRT需求减少驱动,但导线翻修率更高。

要点

  • 传导系统起搏较右室间隔起搏显著降低起搏诱导性心肌病、CRT升级、心衰住院和全因死亡复合终点。
  • 获益主要来自起搏诱导性心肌病减少和CRT升级需求降低,心衰住院和全因死亡无显著差异。
  • 传导系统起搏组导线翻修率更高(7.9% vs 1.0%,P=0.017),需权衡获益与操作风险。

核心结论

  • 在无CRT指征的房室传导阻滞患者中,传导系统起搏较右室间隔起搏显著降低主要复合终点事件率,支持其作为 upfront 起搏技术。

研究设计与样本

  • 随机对照试验,纳入202例有起搏指征的房室传导阻滞且无CRT指征患者,1:1随机分配至右室间隔起搏或传导系统起搏。
  • 传导系统起搏在101例中成功89例(88.1%),平均随访25.2±11.8个月。

主要发现

  • 主要复合终点(起搏诱导性心肌病、升级至双室CRT、心衰住院、全因死亡)事件率:传导系统起搏7.17 vs 右室间隔起搏20.69事件/100人年(HR 0.35,95%CI 0.19-0.64,P<0.001)。
  • 起搏诱导性心肌病事件率:传导系统起搏4.58 vs 右室间隔起搏14.69事件/100人年(HR 0.31,95%CI 0.15-0.67,P=0.002)。
  • 升级至双室CRT事件率:传导系统起搏0 vs 右室间隔起搏1.92事件/100人年(HR 1.65e-9,95%CI 0-∞,P=0.043)。
  • 心衰住院事件率:传导系统起搏0.48 vs 右室间隔起搏2.92事件/100人年(HR 0.16,95%CI 0.02-1.37,P=0.057)。
  • 全因死亡事件率:传导系统起搏2.86 vs 右室间隔起搏4.72事件/100人年(HR 0.61,95%CI 0.22-1.69,P=0.337);导线翻修传导系统起搏8例(7.9%)vs 右室间隔起搏1例(1.0%),P=0.017。

临床怎么用

  • 对于有起搏指征的房室传导阻滞患者,传导系统起搏可作为优于右室间隔起搏的 upfront 起搏策略,以降低起搏诱导性心肌病和CRT升级风险。
  • 选择传导系统起搏时需考虑导线翻修风险较高,并关注心衰住院和死亡获益尚不显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with atrioventricular (AV) block receiving right ventricular (RV) pacing are at risk of pacing-induced cardiomyopathy (PICM), need for upgrade to biventricular cardiac resynchronization therapy (CRT), heart failure hospitalization (HFH), and mortality. Conduction system pacing (CSP) is a promising pacing strategy to mitigate these adverse outcomes. OBJECTIVES: The aim of this study was to compare the clinical outcomes between RV septal pacing (RVsP) and CSP. METHODS: A randomized controlled trial (RCT) was performed in 202 consecutive patients with pacing indication for AV block without CRT indication, with a 1:1 randomization allocation ratio between RVsP and CSP. The primary outcome was a composite endpoint of PICM, upgrade to biventricular CRT, HFH, and all-cause mortality. This trial was registered with the Australian New Zealand Clinical Trials Registry. RESULTS: CSP was successful in 89 of 101 patients (88.1%). After a mean follow-up period of 25.2 ± 11.8 months, CSP was associated with lower composite endpoint (7.17 vs 20.69 events per 100 person-years; HR: 0.35; 95% CI: 0.19-0.64; P < 0.001) primarily driven by lower PICM (CSP 4.58 vs RVsP 14.69 events per 100-person-years; HR: 0.31; 95% CI: 0.15-0.67; P = 0.002) and need for CRT upgrade (0 vs 1.92 events per 100-person-years; HR: 1.65e-9; 95% CI: 0-∞; P = 0.043). There was no difference in HFH (CSP 0.48 vs RVsP 2.92 events per 100-person years; HR: 0.16; 95% CI: 0.02-1.37, P = 0.057) or all-cause mortality (CSP 2.86 vs RVsP 4.72 events per 100-person-years; HR: 0.61; 95% CI: 0.22-1.69; P = 0.337). Lead revision occurred more with CSP (8 patients [7.9%] vs 1 patient [1.0%]; P = 0.017). CONCLUSIONS: This RCT demonstrates the superiority of CSP over RVsP in achieving improved clinical outcomes and supports the indication of CSP as an upfront pacing technique for patients with AV block. (CSPACE: A Randomised Controlled Trial Comparing Right Ventricular Pacing with Conduction System Pacing; ACTRN12619001613190).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Chow CLD, Wong C, Sutherland N, et al. Clinical Outcomes of Conduction System Pacing vs Right Ventricular Septal Pacing in Atrioventricular Block: The CSPACE Randomized Controlled Trial. J Am Coll Cardiol. 2025. PMID: 40835365. doi:10.1016/j.jacc.2025.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。